Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure Licenses Colorectal Cancer ASRs From TDT

NEW YORK (GenomeWeb News) — DiagnoCure said yesterday that it plans to develop and sell two molecular diagnostic tests for cancer that it licensed from Targeted Diagnostics and Therapeutics.
 
DiagnoCure said the tests are designed to detect guanylyl cyclase C, or GCC. The company said the GCC gene appears normally in cells lining the intestines, but has only been found outside the intestine when colorectal cancer has metastasized.
 
Under the agreement, Quebec-based DiagnoCure will develop the tests as home-brew ASRs in TDT’s CLIA-certified lab.
 
Along with other, undisclosed terms, DiagnoCure agreed to pay TDT around $2.2 million worth of its shares, priced at CA$4.30 ($3.87) apiece.
 
TDT also will receive milestone and royalty payments from any revenue generated from sales of the tests.
 
TDT, based in West Chester, Pa., was formed in 1994 to commercialize technology developed by Scott Waldman of the Thomas Jefferson University of Philadelphia. 
 
DiagnoCure said that Waldman has found the GCC-based tests to be 95 to 100 percent accurate in detecting the spread or recurrence of colon cancer in the lymph nodes or in blood.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.